ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy

Guan, Shaoxing; Chen, Xi; Chen, Youhao; Wan, Guohui; Su, Qibiao; Liang, Heng; Yang, Yunpeng; Fang, Wenfeng; Huang, Yan; Zhao, Hongyun; Zhuang, Wei; Liu, Shu; Wang, Fei; Feng, Wei; Zhang, Xiaoxu; Huang, Min*; Wang, Xueding*; Zhang, Li*广东药学院; 广州中医药大学; 中山大学
Acta Pharmaceutica Sinica B2022-9DOI: 10.1016/j.apsb.2022.02.006
4被引6阅读
引用收藏
分享

摘要

Hepatotoxicity is a common side effect for patients treated with gefitinib, but the related pathogenesis is unclear and lacks effective predictor and management strategies. A multi-omics approach integrating pharmacometabolomics, pharmacokinetics and pharmacogenomics was employed in nonsmall cell lung cancer patients to identify the effective predictor for gefitinib-induced hepatotoxicity and explore optional therapy substitution. Here, we found that patients with rs4946935 AA, located in Forkhead Box O3 (FOXO3) which is a well-known autophagic regulator, had a higher risk of hepatotoxicity than those with the GA or GG variant (OR Z18.020, 95%CIZ 2.473 to 459.1784, PZ0.018) in a gefitinib-concentration dependent pattern. Furthermore, functional experiments identified that rs4946935_Lambda impaired the expression of FOXO3 by inhibiting the promotor activity, increasing the threshold of autophagy initiation and inhibiting the autophagic activity which contributed to gefitinibinduced liver injury. In contrast, erlotinib-induced liver injury was independent on the variant and expression levels of FOXO3. This study reveals that FOXO3 mutation, leading to autophagic imbalance, plays important role in gefitinib-induced hepatotoxicity, especially for patients with high concentration of gefitinib. In conclusion, FOXO3 mutation is an effective predictor and erlotinib might be an appropriately and well-tolerated treatment option for patients carrying rs4946935 AA. (c) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

学科与关键词

关键词
GefitinibHepatotoxicityPharmacometabolomicPharmacokineticsPharmacogenomicsFOXO3Autophagy
相关
加载中…
  • Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics
    Feng, Wei; Chen, Xi; Guan, Shao-xing; Ruan, Hong-lian; Huang, Yan; Zhang, Hui-zhen; Yang, Yun-peng; Fang, Wen-feng; Zhao, Hong-yun; Zhuang, Wei; Xin, Shuang; Chen, You-hao; Wang, Fei; Gao, Yue; Huang, Min*; Wang, Xue-ding*; Zhang, Li*Acta Pharmacologica Sinica, 2022, 43(7): 1857-1864.被引 2
  • Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial
    Li, Xiang-Meng; Li, Wen-Feng; Lin, Jun-Tao; Yan, Hong-Hong; Tu, Hai-Yan; Chen, Hua-Jun; Wang, Bin-Chao; Wang, Zhen; Zhou, Qing; Zhang, Xu-Chao; Su, Jian; Chen, Rui-Lian; Wu, Yi-Long*; Yang, Jin-Ji*Clinical Lung Cancer, 2021, 22(2): 100-+.被引 28
  • The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors
    Chen, Youhao; Lin, Yaobin; Guan, Shaoxing; Zhao, Zerui; Lin, Daren; Guan, Jin; Zhou, Chengzhi; Liu, Junling; Cao, Xiaolong; Lin, Zhichao; Chen, Diyao; Shang, Jianbiao; Zhang, Weijian; Chen, Huohui; Chen, Likun; Ma, Shudong; Gu, Lijia; Zhao, Jian; Huang, Min*; Wang, Xueding*; Long, Hao*Drug Metabolism and Disposition, 2023, 51(12): 1583-1590.
查看全部 →

发表信息

论文状态
公开发表
期刊
Acta Pharmaceutica Sinica B
发表日期
2022-09
卷期
第 12 卷, 第 9 期
页码
3639-3649
DOI
10.1016/j.apsb.2022.02.006
期刊收录
CSCD-C.CAST-L
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81973398, 81473283, 81730103, 81573507, 82020108031]; National Key Research and Development Program [2017YFC0909300, 2016YFC0905000]; Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030]; Science and Technology Program of Guangzhou [201607020031]; National Engineering and Technology Research Center for New drug Druggability Evaluation (Seed Program of Guangdong Province) [2017B090903004]; 111 project [B16047]; China Postdoctoral Science Foundation [2019M66324, 2020M683140, 2020M683139]; Keyue Wang (Faculty of life science and medicine, King's College of London)

作者

  • G

    Guan, Shaoxing (第一作者)

    sun yat sen univ

  • C

    Chen, Xi

    sun yat sen univ

查看全部 18 位作者收起作者
  • C

    Chen, Youhao

    sun yat sen univ

  • W

    Wan, Guohui

    sun yat sen univ

  • S

    Su, Qibiao

    guangdong pharmaceut univ

  • L

    Liang, Heng

    sun yat sen univ

  • Y

    Yang, Yunpeng

    sun yat sen univ

  • F

    Fang, Wenfeng

    sun yat sen univ

  • H

    Huang, Yan

    sun yat sen univ

  • Z

    Zhao, Hongyun

    sun yat sen univ

  • Z

    Zhuang, Wei

    sun yat sen univ

  • L

    Liu, Shu

    sun yat sen univ

  • W

    Wang, Fei

    2 · guangzhou univ chinese med

  • F

    Feng, Wei

    sun yat sen univ

  • Z

    Zhang, Xiaoxu

    sun yat sen univ

  • H

    Huang, Min (通讯)

    sun yat sen univ

  • W

    Wang, Xueding (通讯)

    sun yat sen univ

  • Z

    Zhang, Li (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417